PARATEK PHARMACEUTICALS INC (PRTK) Fundamental Analysis & Valuation
NASDAQ:PRTK • US6993743029
Current stock price
2.23 USD
+0.04 (+1.83%)
At close:
2.23 USD
0 (0%)
After Hours:
This PRTK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. PRTK Profitability Analysis
1.1 Basic Checks
- PRTK had negative earnings in the past year.
- In the past year PRTK has reported a negative cash flow from operations.
1.2 Ratios
- The profitability ratios for PRTK are negative, so there is not much use analyzing them.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- PRTK's Gross Margin of 85.71% is amongst the best of the industry. PRTK outperforms 89.57% of its industry peers.
- In the last couple of years the Gross Margin of PRTK has grown nicely.
- The Profit Margin and Operating Margin are not available for PRTK so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.71% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.73%
GM growth 5YN/A
2. PRTK Health Analysis
2.1 Basic Checks
- PRTK does not have a ROIC to compare to the WACC, probably because it is not profitable.
- PRTK has more shares outstanding than it did 1 year ago.
- Compared to 1 year ago, PRTK has a worse debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of -9.64, we must say that PRTK is in the distress zone and has some risk of bankruptcy.
- PRTK's Altman-Z score of -9.64 is on the low side compared to the rest of the industry. PRTK is outperformed by 75.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.64 |
ROIC/WACCN/A
WACC7.65%
2.3 Liquidity
- A Current Ratio of 0.52 indicates that PRTK may have some problems paying its short term obligations.
- Looking at the Current ratio, with a value of 0.52, PRTK is doing worse than 92.42% of the companies in the same industry.
- PRTK has a Quick Ratio of 0.52. This is a bad value and indicates that PRTK is not financially healthy enough and could expect problems in meeting its short term obligations.
- PRTK has a Quick ratio of 0.46. This is amonst the worse of the industry: PRTK underperforms 92.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.52 | ||
| Quick Ratio | 0.46 |
3. PRTK Growth Analysis
3.1 Past
- PRTK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.67%, which is quite impressive.
- PRTK shows a strong growth in Revenue. In the last year, the Revenue has grown by 59.83%.
- The Revenue has been growing by 66.25% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)35.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.24%
Revenue 1Y (TTM)59.83%
Revenue growth 3Y113.19%
Revenue growth 5Y66.25%
Sales Q2Q%34.94%
3.2 Future
- PRTK is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.93% yearly.
- PRTK is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.58% yearly.
EPS Next Y32.14%
EPS Next 2Y41.42%
EPS Next 3Y26.53%
EPS Next 5Y31.93%
Revenue Next Year9.93%
Revenue Next 2Y25.23%
Revenue Next 3Y14.33%
Revenue Next 5Y22.58%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. PRTK Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for PRTK. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as PRTK's earnings are expected to grow with 26.53% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y26.53%
5. PRTK Dividend Analysis
5.1 Amount
- No dividends for PRTK!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PRTK Fundamentals: All Metrics, Ratios and Statistics
2.23
+0.04 (+1.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-03 2023-08-03/bmo
Earnings (Next)11-01 2023-11-01/bmo
Inst Owners0.15%
Inst Owner Change361.84%
Ins Owners6.47%
Ins Owner Change0%
Market Cap127.82M
Revenue(TTM)177.00M
Net Income(TTM)-62.73M
Analysts80
Price Target3.16 (41.7%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.04%
Min EPS beat(2)18.3%
Max EPS beat(2)21.78%
EPS beat(4)2
Avg EPS beat(4)-53.61%
Min EPS beat(4)-226.05%
Max EPS beat(4)21.78%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)8.81%
Min Revenue beat(2)1.8%
Max Revenue beat(2)15.83%
Revenue beat(4)3
Avg Revenue beat(4)5.25%
Min Revenue beat(4)-13.37%
Max Revenue beat(4)16.74%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-41.87%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.96%
EPS NY rev (1m)14.05%
EPS NY rev (3m)22.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.68%
Revenue NY rev (1m)3.71%
Revenue NY rev (3m)5.86%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.72 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.1
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS3.09
BVpS-3.51
TBVpS-3.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.71% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.73%
GM growth 5YN/A
F-Score5
Asset Turnover1.21
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 10.39% | ||
| Cap/Sales | 0.02% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.52 | ||
| Quick Ratio | 0.46 | ||
| Altman-Z | -9.64 |
F-Score5
WACC7.65%
ROIC/WACCN/A
Cap/Depr(3y)56.09%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.37%
Cap/Sales(5y)0.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.24%
EPS Next Y32.14%
EPS Next 2Y41.42%
EPS Next 3Y26.53%
EPS Next 5Y31.93%
Revenue 1Y (TTM)59.83%
Revenue growth 3Y113.19%
Revenue growth 5Y66.25%
Sales Q2Q%34.94%
Revenue Next Year9.93%
Revenue Next 2Y25.23%
Revenue Next 3Y14.33%
Revenue Next 5Y22.58%
EBIT growth 1Y34.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y78.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y78.4%
OCF growth 3YN/A
OCF growth 5YN/A
PARATEK PHARMACEUTICALS INC / PRTK Fundamental Analysis FAQ
What is the ChartMill fundamental rating of PARATEK PHARMACEUTICALS INC (PRTK) stock?
ChartMill assigns a fundamental rating of 2 / 10 to PRTK.
What is the valuation status for PRTK stock?
ChartMill assigns a valuation rating of 1 / 10 to PARATEK PHARMACEUTICALS INC (PRTK). This can be considered as Overvalued.
What is the profitability of PRTK stock?
PARATEK PHARMACEUTICALS INC (PRTK) has a profitability rating of 1 / 10.
Can you provide the financial health for PRTK stock?
The financial health rating of PARATEK PHARMACEUTICALS INC (PRTK) is 0 / 10.